Nutriband Inc. (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, announced that its CEO and Co-Founder Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit. The presentation is part of the CEO Spotlight event, scheduled for Aug. 26, during the two-day summit held at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia. The summit brings together leaders across biotechnology, medical technology, research, manufacturing, and investment sectors, providing a platform for discussing innovations and trends in life sciences.
Nutriband is developing AVERSA, its abuse-deterrent transdermal technology designed to incorporate aversive agents into patches. This technology aims to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, particularly opioids. The lead product under development is an abuse-deterrent fentanyl patch that utilizes AVERSA. By integrating aversive agents, the patch is intended to deter tampering and reduce the potential for recreational use, addressing a critical public health concern.
The participation in the summit highlights Nutriband's commitment to advancing solutions that combat opioid abuse, a significant issue in the United States and globally. The presentation offers an opportunity for the company to showcase its innovative technology to a diverse audience of industry experts, potential partners, and investors. The summit's focus on collaboration and cutting-edge research makes it an ideal venue for Nutriband to share its progress and future plans.
According to the press release, the latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB. Additionally, the full press release can be viewed at https://ibn.fm/Un3ax. The company's website is www.nutriband.com, where more information about its product pipeline can be found.
This announcement is important as it underscores Nutriband's active engagement in the life sciences community and its ongoing efforts to bring its abuse-deterrent technology to market. With the opioid crisis continuing to affect communities, innovations like AVERSA could play a vital role in mitigating risks associated with prescription opioids. The CEO's presence at the summit may also attract investor attention, potentially impacting the company's visibility and future partnerships.
